Sort   by:  
 Page size 
UnknownBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Not available
S-EPMC6286161 | biostudies-literature
UnknownPhase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Not available
S-EPMC4815889 | biostudies-literature
UnknownTreatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer.
Not available
S-EPMC8774125 | biostudies-literature
UnknownTrifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
Not available
S-EPMC8453191 | biostudies-literature
UnknownEfficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Not available
S-EPMC10265605 | biostudies-literature
UnknownBRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
Not available
S-EPMC8194012 | biostudies-literature
UnknownPD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Not available
S-EPMC9167784 | biostudies-literature
UnknownCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Not available
S-EPMC5882509 | biostudies-literature
UnknownEfficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study.
Not available
S-EPMC12574357 | biostudies-literature
UnknownClinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Not available
S-EPMC11379635 | biostudies-literature
Sort   by:  
 Page size